T0	Interventions 18 66	granulocyte-macrophage colony-stimulating factor
T1	Interventions 279 287	(GM-CSF)
T2	Interventions 533 671	Zidovudine was discontinued in group A patients before instituting GM-CSF treatment and was restarted in a graduated fashion over 4 weeks.
T3	Interventions 672 775	Group B patients continued on full-dose (1,200 mg/d) zidovudine therapy while beginning GM-CSF therapy.